advanced intrahepatic cholangiocarcinoma
Conditions
Interventions
Sponsors
Kui Wang
Eligibility
Sex/Gender
All
Age
18 Years to 78 Years
Inclusion criteria
Inclusion criteria: 1. Aged 18 to 78 years, male or female; 2. Advanced intrahepatic cholangiocarcinoma patients received one first-line treatment failure; 3. ECOG score 0 or 1; 4. Expected survival> 12 weeks; 5. Swallow pills normally; 6. All patients should provide tumor tissue samples before enrollment to take the gene analysis (VEGFR1, VEGFR2, VEGFR3, FGFR, PDGFRß, c-Kit); 7. One lesion without receiving radiotherapy can be measured at least; 8. Organ function should meet the following requirement: Marrow: (ANC)=1.5×9E/L,PLT= 100×9E/L,HB=9g/dL; Liver:TBIL=1.5 times normal value,AST and ALT=2.5 times normal value;? Child-Pugh A; Cr=1.5 times normal value; INR and APTT =1.5 times normal value; UCG:LVEF >50%; 9. Non-pregnant women and Men and women with reproductive function use highly effective contraceptive methods; 10. The subjects volunteered to participate in the study and signed the informed consent, with good compliance and follow-up.
Exclusion criteria
Exclusion criteria: 1. Patients received anti-VEGFR TKI treatment; 2. Patients with central system metastasis; 3. Patients who have participated in or are participating in clinical trials of other drugs/therapies in late 4 weeks; 4. Patients who have received surgery and don't recover from the adverse effect in late 4 weeks; 5. Patients who are taking the immunosuppressant, or systemic hormone therapy for immunosuppressive purposes or taked this in 2 weeks; 6. Patients who have a history of malignant tumors other than ICC in the past 5 years; 7. Patients who received hematopoietic stimulating factors(G-CSF/EPO) within 1 week; 8. HIV antibody or treponema pallidum antibody test was positive; 9. Be allergic to anrotinib and any adjuvants; 10. Massive hydrothorax or ascites with clinical symptoms requiring symptomatic management; 11. The investigator determined that poor compliance or other conditions made the patient unsuitable for the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| objective remission rate; | — |
Countries
China
Contacts
Public ContactKui Wang
Eastern Hepatobiliary Surgery Hospital
Outcome results
None listed